These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37061210)

  • 1. Development of a compounded propofol nanoemulsion using multiple non-invasive process analytical technologies.
    Rooimans T; Damen M; Markesteijn CMA; Schuurmans CCL; de Zoete NHC; van Hasselt PM; Hennink WE; van Nostrum CF; Hermes M; Besseling R; Vromans H
    Int J Pharm; 2023 Jun; 640():122960. PubMed ID: 37061210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospital Production of Sterile 2% Propofol Nanoemulsion: Proof of Concept.
    Cèbe A; Dessane B; Gohier P; Bernadou JM; Venet A; Xuereb F; Crauste-Manciet S
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexistence of oil droplets and lipid vesicles in propofol drug products.
    Wu Y; Manna S; Petrochenko P; Koo B; Chen L; Xu X; Choi S; Kozak D; Zheng J
    Int J Pharm; 2020 Mar; 577():118998. PubMed ID: 31935473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical properties and stability of two emulsion formulations of propofol.
    Han J; Davis SS; Washington C
    Int J Pharm; 2001 Mar; 215(1-2):207-20. PubMed ID: 11250106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Simple and Noninvasive DOSY NMR Method for Droplet Size Measurement of Intact Oil-In-Water Emulsion Drug Products.
    Patil SM; Li V; Peng J; Kozak D; Xu J; Cai B; Keire DA; Chen K
    J Pharm Sci; 2019 Feb; 108(2):815-820. PubMed ID: 30291851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions.
    Nemec K; Germ E; Schulz-Siegmund M; Ortner A
    Pharmazie; 2009 Feb; 64(2):94-7. PubMed ID: 19320281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propofol: the challenges of formulation.
    Baker MT; Naguib M
    Anesthesiology; 2005 Oct; 103(4):860-76. PubMed ID: 16192780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new alternative for intravenous lipid emulsion 20% w/w from superolein oil and its effect on lipid and liver profiles in an animal model.
    Amran MHH; Zulfakar MH; Danik MF; Abdullah MSP; Shamsuddin AF
    Daru; 2019 Jun; 27(1):191-201. PubMed ID: 31020546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free radical and drug oxidation products in an intensive care unit sedative: propofol with sulfite.
    Baker MT; Gregerson MS; Martin SM; Buettner GR
    Crit Care Med; 2003 Mar; 31(3):787-92. PubMed ID: 12626985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation and Evaluation of Multidose Propofol Nanoemulsion Using Statistically Designed Experiments.
    Hota SS; Pattnaik S; Mallick S
    Acta Chim Slov; 2020 Mar; 67(1):179-188. PubMed ID: 33558914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetically stable propofol emulsions with reduced free drug concentration for intravenous delivery.
    Damitz R; Chauhan A
    Int J Pharm; 2015; 486(1-2):232-41. PubMed ID: 25839419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the addition of lignocaine on propofol emulsion stability.
    Lilley EM; Isert PR; Carasso ML; Kennedy RA
    Anaesthesia; 1996 Sep; 51(9):815-8. PubMed ID: 8882240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of lidocaine on the globule size distribution of propofol emulsions.
    Park JW; Park ES; Chi SC; Kil HY; Lee KH
    Anesth Analg; 2003 Sep; 97(3):769-771. PubMed ID: 12933399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.
    Knibbe CA; Zuideveld KP; DeJongh J; Kuks PF; Aarts LP; Danhof M
    Clin Pharmacol Ther; 2002 Dec; 72(6):670-84. PubMed ID: 12496748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
    Trissel LA; Gilbert DL; Martinez JF
    Am J Health Syst Pharm; 1997 Jun; 54(11):1287-92. PubMed ID: 9179349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMOFlipid vs Intralipid 20%: Effect of Mixed-Oil vs Soybean-Oil Emulsion on Parenteral Nutrition-Associated Cholestasis in the Neonatal Population.
    Jackson RL; White PZ; Zalla J
    JPEN J Parenter Enteral Nutr; 2021 Feb; 45(2):339-346. PubMed ID: 32391595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of propofol for sedation of non-mechanically ventilated patients in non-critical care areas by anesthesia providers and non-anesthesia trained healthcare providers: a systematic review.
    Gollaher T; Baker K
    JBI Libr Syst Rev; 2012; 10(46):2944-2997. PubMed ID: 27820497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetically based propofol dosing strategy for sedation of the critically ill, mechanically ventilated pediatric patient.
    Reed MD; Yamashita TS; Marx CM; Myers CM; Blumer JL
    Crit Care Med; 1996 Sep; 24(9):1473-81. PubMed ID: 8797618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of alternative intravenous lipid emulsion in clinical outcome in non-critically ill patients.
    Salazar E; Ghosh P; Tan V; Pang T; Poh BY; Tan LB; Loy KL; Chong J; Beh HL; Ng HM; Ling KL; Wang YT
    Clin Nutr ESPEN; 2019 Oct; 33():42-46. PubMed ID: 31451274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propofol: an immunomodulating agent.
    Marik PE
    Pharmacotherapy; 2005 May; 25(5 Pt 2):28S-33S. PubMed ID: 15899746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.